Etonogestrel and Glecaprevir/Pibrentasvir Interaction

Understanding the Etonogestrel and Glecaprevir/Pibrentasvir Interaction

FDA-approved prescribing information for these two drugs flags their combination as a moderate-severity interaction. Etonogestrel belongs to the Progestin (Implant) class and Glecaprevir/Pibrentasvir belongs to the NS3/4A/NS5A Inhibitor (HCV) class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Taking these medicines together can cause your liver enzymes to rise, which is a sign of liver stress. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Etonogestrel has 29 total documented interactions on file in this dataset, and Glecaprevir/Pibrentasvir has 38. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Your doctor should monitor your liver health closely with blood tests if you take these together. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Etonogestrel or Glecaprevir/Pibrentasvir based on a web page, speak with your prescriber or pharmacist before making any change.